Immunowork's proprietary T-E drug design platform was developed to design a new class of multifunctional T-E pharmaceuticals containing both targeting (T) and effector (E) functional moieties on a single molecule to address the therapeutic needs in cancer, pathological blood clots, diabetes, and other severe clinical conditions. Aiming to file our first IND product in 2021 we have 5 candidates in IND enabling phase. With a flexible multi-arm linker system, different functional modules can be combined based on therapeutic needs, and the T-E drugs can be designed with the exact element ratio to improve product homogeneity, drug payloads, target-binding valency, and the consistency in the manufacturing process. Therefore, the T-E configurations are expected to achieve increased efficacy and safety.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
TE-8104 ultra long-acting GLP-1 analog
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):